<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004165</url>
  </required_header>
  <id_info>
    <org_study_id>NU 97H6T</org_study_id>
    <secondary_id>NU-97H6T</secondary_id>
    <secondary_id>NCI-G99-1632</secondary_id>
    <nct_id>NCT00004165</nct_id>
  </id_info>
  <brief_title>Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to&#xD;
      give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase III trial to study the effectiveness of melphalan followed by peripheral stem&#xD;
      cell transplantation in treating patients who have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Administer standard, high dose melphalan safely in a closely monitored setting in&#xD;
           patients with responsive multiple myeloma.&#xD;
&#xD;
        -  Determine the cost and time effectiveness in the collection of sufficient peripheral&#xD;
           blood stem cells (PBSC) for two high dose melphalan therapies and PBSC transplantations&#xD;
           in this patient population.&#xD;
&#xD;
      OUTLINE: Patients not in remission receive 3-6 courses of remission induction therapy&#xD;
      consisting of either an anthracycline/glucocorticoid regimen or high dose glucocorticoids.&#xD;
&#xD;
      At 21-45 days following induction therapy, patients receive filgrastim (G-CSF) subcutaneously&#xD;
      daily for 4 days followed by daily peripheral blood stem cell (PBSC) collection beginning on&#xD;
      day 4 and continuing until the target number of cells is reached.&#xD;
&#xD;
      At 5 days to 6 weeks following PBSC collection, patients receive high dose melphalan IV over&#xD;
      2 hours for 2 consecutive days. At 36-48 hours following completion of melphalan, patients&#xD;
      receive infusion of PBSC followed by G-CSF subcutaneously daily until blood counts recover.&#xD;
&#xD;
      At 3 months to 5 years following high dose therapy and PBSC infusion, patients with evidence&#xD;
      of disease progression receive an additional treatment with high dose melphalan followed by&#xD;
      PBSC infusion as in the first course.&#xD;
&#xD;
      Patients are followed at 30-45 days, 6 months, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60-120 patients will be accrued for this study over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosed active multiple myeloma defined by:&#xD;
&#xD;
               -  Lytic disease&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Hypercalcemia&#xD;
&#xD;
               -  Secondary renal insufficiency&#xD;
&#xD;
               -  More than 400 mg/24 hours of urinary protein excretion&#xD;
&#xD;
               -  Symptomatic hyperviscosity&#xD;
&#xD;
          -  If previously treated, refractory to no more than 1 regimen&#xD;
&#xD;
          -  Primary amyloidosis without subsequent multiple myeloma allowed&#xD;
&#xD;
               -  Abnormal renal function allowed if due to primary disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min if no renal impairment&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac function that would preclude study&#xD;
&#xD;
          -  LVEF greater than 45%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary function that would preclude study&#xD;
&#xD;
          -  FVC greater than 60% predicted&#xD;
&#xD;
          -  DLCO greater than 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No greater than 18 months of prior alkylator exposure&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 3 prior treatment regimens allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Traynor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

